Sixfold Bioscience
Sixfold Bioscience, based in London, specializes in the development of innovative drug delivery systems for RNA therapeutics, utilizing a unique platform called Mergo® enhanced by AI and machine learning.
Company Overview
Sixfold Bioscience, based in London, United Kingdom, is a healthcare company specializing in drug discovery and delivery. The company focuses on the commercialization of patented drug delivery systems for RNA therapeutics, including siRNAs for gene silencing and mRNAs for gene expression. With a team of 27 professionals, Sixfold Bioscience combines evolutionary principles and AI to develop innovative solutions in RNA therapies.
RNA Therapeutics and Delivery Systems
Sixfold Bioscience concentrates on RNA therapeutics inspired by evolution and refined through artificial intelligence. A significant achievement of the company is the development of Mergo®, a programmable RNA tag designed to encode RNA modifications and influences the delivery destination effectively. This approach leverages biology's natural processes rather than forcing cellular entry, representing a radical shift in RNA delivery mechanisms.
Machine Learning and AI in RNA Delivery
The company employs machine learning to create a manufacturable library of over 100,000 Mergo® variants for diverse optimization. This innovative practice allows the company to tailor RNA delivery systems and solve problems effectively. By integrating AI and automation, Sixfold Bioscience continuously tests multiple Mergos within one biological model at cellular resolution, facilitating the exploration of complex biological questions in parallel.
The Mergo® Technology
Mergo® represents a groundbreaking approach to RNA delivery, utilizing programmable tags to encode specific RNA modifications and design elements. This technology reflects the company's pioneering methodology, working harmoniously with natural biological processes. Mergo® technology benefits from innovative chemistry and lab automation, enabling high-throughput generation and optimizing RNA delivery mechanisms.
Founding and Growth
Sixfold Bioscience participated in the Y-Combinator Winter 2018 batch, marking a significant milestone in its early-stage development. With operations primarily in the United Kingdom and Europe, the company has expanded its team to 27 members and established itself as a prominent player in the RNA delivery and therapeutic industry.